Cargando…

The Road towards Polyclonal Anti-SARS-CoV-2 Immunoglobulins (Hyperimmune Serum) for Passive Immunization in COVID-19

Effective treatments specific for COVID-19 are still lacking. In the setting of passive immunotherapies based on neutralizing antibodies (nAbs), randomized controlled trials of COVID-19 convalescent plasma (CCP) anti-SARS-CoV-2 Spike protein monoclonal antibodies (mAb), which have been granted emerg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Focosi, Daniele, Tuccori, Marco, Franchini, Massimo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7918959/ https://www.ncbi.nlm.nih.gov/pubmed/33671893 http://dx.doi.org/10.3390/life11020144

Ejemplares similares

Efficacy of High-Dose Polyclonal Intravenous Immunoglobulin in COVID-19: A Systematic Review
por: Focosi, Daniele, et al.
Publicado: (2022)

Polyclonal immunoglobulins for COVID-19 pre-exposure prophylaxis in immunocompromised patients
por: Focosi, Daniele, et al.
Publicado: (2023)

Production and Quality Assurance of Human Polyclonal Hyperimmune Immunoglobulins Against SARS-CoV-2
por: Burnouf, Thierry, et al.
Publicado: (2022)

Anti-SARS-CoV-2 hyperimmune immunoglobulins, an urgent strategic choice
Publicado: (2020)

Prescription of Anti-Spike Monoclonal Antibodies in COVID-19 Patients with Resistant SARS-CoV-2 Variants in Italy
por: Focosi, Daniele, et al.
Publicado: (2022)

Immunoglobulines hyperimmunes anti-SARS-CoV-2, un choix stratégique urgent
Publicado: (2020)

Passive Transfer of Animal-Derived Polyclonal Hyperimmune Antibodies Provides Protection of Mice from Lethal Lassa Virus Infection
por: Oestereich, Lisa, et al.
Publicado: (2023)

Anti-SARS-CoV-2 hyperimmune plasma workflow
por: Annamaria, Petrungaro, et al.
Publicado: (2020)

Antibodies and SARS-CoV-2: New Data on Diagnostics and Therapeutics
por: Focosi, Daniele, et al.
Publicado: (2022)

SARS-CoV-2 infection, vaccination and acquired hemophilia: Reply
por: Franchini, Massimo, et al.
Publicado: (2023)

Production of hyperimmune anti-SARS-CoV-2 intravenous immunoglobulin from pooled COVID-19 convalescent plasma
por: Ali, Shaukat, et al.
Publicado: (2021)

Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline
por: Tuccori, Marco, et al.
Publicado: (2020)

Respiratory delivery of passive immunotherapies for SARS-CoV-2 prophylaxis and therapy
por: Focosi, Daniele, et al.
Publicado: (2023)

Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development
por: de Alwis, Ruklanthi, et al.
Publicado: (2020)

SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies
por: Focosi, Daniele, et al.
Publicado: (2021)

Epitope diversity of SARS-CoV-2 hyperimmune intravenous human immunoglobulins and neutralization of variants of concern
por: Tang, Juanjie, et al.
Publicado: (2021)

Comparison of SARS-CoV-2 Hyperimmune Immunoglobulins Following Infection Plus Vaccination vs Infection
por: Bellusci, Lorenza, et al.
Publicado: (2023)

Heterologous Hyperimmune Polyclonal Antibodies Against SARS-CoV-2: A Broad Coverage, Affordable, and Scalable Potential Immunotherapy for COVID-19
por: Alape-Girón, Alberto, et al.
Publicado: (2021)

Association between SARS-CoV-2 infection or vaccination and acquired hemophilia A: A case report and literature update
por: Franchini, Massimo, et al.
Publicado: (2023)

Monoclonal antibody therapies against SARS-CoV-2
por: Focosi, Daniele, et al.
Publicado: (2022)

Production of anti‐SARS‐CoV‐2 hyperimmune globulin from convalescent plasma
por: Vandeberg, Peter, et al.
Publicado: (2021)

Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources
por: Sullivan, David J., et al.
Publicado: (2022)

Convalescent plasma (hyperimmune immunoglobulin) for COVID-19 management: An update
por: Chavda, Vivek P., et al.
Publicado: (2023)

Human immunoglobulin from transchromosomic bovines hyperimmunized with SARS-CoV-2 spike antigen efficiently neutralizes viral variants
por: Liu, Zhuoming, et al.
Publicado: (2021)

Passive Monoclonal and Polyclonal Antibody Therapies
por: Pelletier, J. Peter R., et al.
Publicado: (2020)

ANTI-DNA ANTIBODIES IN HYPERIMMUNIZED RABBITS
por: Christian, Charles L., et al.
Publicado: (1965)

Cochrane corner: convalescent plasma or hyperimmune immunoglobulin for people with COVID-19
por: Nnaji, Chukwudi Arnest, et al.
Publicado: (2020)

Hyperimmune anti-HBs plasma as alternative to commercial immunoglobulins for prevention of HBV recurrence after liver transplantation
por: Bihl, Florian, et al.
Publicado: (2010)

Understanding the treatment benefit of hyperimmune anti-influenza intravenous immunoglobulin (Flu-IVIG) for severe human influenza
por: Vanderven, Hillary A., et al.
Publicado: (2023)

Treatment with hyperimmune equine immunoglobulin or immunoglobulin fragments completely protects rodents from Ebola virus infection
por: Zheng, Xuexing, et al.
Publicado: (2016)

Polyclonal hyper immunoglobulin: A proven treatment and prophylaxis platform for passive immunization to address existing and emerging diseases
por: Tharmalingam, Tharmala, et al.
Publicado: (2021)

Elevated serum polyclonal immunoglobulin free light chains in patients with severe asthma
por: Basile, Umberto, et al.
Publicado: (2023)

Therapeutic potential of convalescent plasma and hyperimmune immunoglobulins against SARS-CoV-2 BQ.1, BQ.1.1, and XBB variants
por: Bellusci, Lorenza, et al.
Publicado: (2023)

Hyperimmunized Chickens Produce Neutralizing Antibodies against SARS-CoV-2
por: Aston, Emily J., et al.
Publicado: (2022)

Immune Maturation Effects on Viral Neutralization and Avidity of Hyperimmunized Equine Anti-SARS-CoV-2 Sera
por: González Viacava, Myriam Belén, et al.
Publicado: (2022)

On the Need to Determine the Contribution of Anti-Nucleocapsid Antibodies as Potential Contributors to COVID-19 Convalescent Plasma Efficacy
por: Focosi, Daniele, et al.
Publicado: (2022)

Screening of Multiple Myeloma by Polyclonal Rabbit Anti-Human Plasmacytoma Cell Immunoglobulin
por: Mu, Bo, et al.
Publicado: (2013)

Subcutaneous anti-COVID-19 hyperimmune immunoglobulin for prevention of disease in asymptomatic individuals with SARS-CoV-2 infection: a double-blind, placebo-controlled, randomised clinical trial
por: Alemany, Andrea, et al.
Publicado: (2023)

Potent Anti‐SARS‐CoV‐2 Efficacy of COVID‐19 Hyperimmune Globulin from Vaccine‐Immunized Plasma
por: Yu, Ding, et al.
Publicado: (2022)

What is the optimal usage of coronavirus disease 2019 convalescent plasma donations?
por: Focosi, Daniele, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_l3cbh6gkt1h1shauem7g53pfhd